Estetrol Hormone Therapy Dosing for Menopause Symptom Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current hormone replacement therapies for alleviating menopause-associated symptoms, particularly vasomotor symptoms (VMS), face challenges in identifying the lowest effective dose of estrogen that balances efficacy with minimal side effects, and there is a need for a safer estrogen alternative.

Innovation Solution

The use of estetrol at a daily dose ranging from 15 mg to 25 mg, considering both frequency and severity of VMS, along with the administration of a progestogenic component when applicable, to effectively alleviate menopause-associated symptoms while maintaining acceptable side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current hormone replacement therapies use estrogen to alleviate menopause symptoms, then efficacy in relieving vasomotor symptoms is improved, but side effects and safety concerns increase

Engineering Contradiction:

Improveefficacy in relieving vasomotor symptomsVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by switching from traditional estrogen compounds to estetrol (E4), a different estrogen compound with altered pharmacological properties. This parameter change in the chemical structure and metabolic profile of the estrogen agent provides therapeutic efficacy while reducing harmful side effects such as hepatic impact and cardiovascular risk

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent utilizes estetrol, a estrogen compound that is naturally produced in the fetus and has a favorable safety profile. By using this alternative estrogen source with different metabolic characteristics, the therapy achieves symptom relief without the long-term safety concerns associated with conventional estrogen HRT

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Reliability

If the dose of estrogen is increased to improve symptom relief, then efficacy is improved, but side effects increase

Engineering Contradiction:

Improvesymptom relief efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the fundamental parameter of the estrogen compound from traditional estrogens to estetrol, which has a different dose-response relationship and side effect profile. This allows for effective symptom management at doses that do not produce the harmful effects seen with conventional estrogen therapy

Inventive Principle:

Principle #35Parameter changes

3Reliability

If traditional estrogen therapy is used to treat menopause symptoms, then vasomotor symptoms are relieved, but impact on hepatic, haemostatic, and metabolic parameters increases

Engineering Contradiction:

Improverelief of menopause symptomsVSAvoidimpact on hepatic, haemostatic, and metabolic parameters

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs estetrol, a estrogen compound with favorable metabolic characteristics that is not associated with the hepatic, haemostatic, and metabolic side effects of traditional estrogens. This alternative agent provides the necessary therapeutic effect while preserving liver function, blood clotting parameters, and metabolic health

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS20260034147A1Compounds and their uses for alleviating menopause-associated symptoms

Publication Date: 2026.02.05 ESTETRA SRL

AI summary

The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component.The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.